Penicillin…He Will Come Home!” the Challenge of Mass Production
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Taming of “49” Big Science in Little Time
The Taming of “49” Big science in little time Recollections of Edward F. Hammel During the Manhattan Project, plutonium was often referred to, simply, as 49. Number 4 was for the last digit in 94 (the atomic number of plutonium) and 9 for the last digit in plutonium-239, the isotope of choice for nuclear weapons. The story that unfolds was adapted from Plutonium Metallurgy at Los Alamos, 1943–1945, as Edward F. Hammel remembers the events of those years. 48 Los Alamos Science Number 26 2000 The Taming of “49” he work in plutonium chemistry tion work was an inevitable conse- the metal could be fabricated into and metallurgy carried out at quence of the nuclear and physical satisfactory weapon components. TLos Alamos (Site Y) between research that was still to be conducted In addition, not until January 1944 1943 and 1945 had a somewhat contro- on the metal. It would clearly have did the first few milligrams of pile- versial history. The controversy was been inefficient and time consuming to produced plutonium arrive at Los about who was going to do what. ship small amounts of plutonium metal Alamos. The first 1-gram shipment At the time Los Alamos was being back to Chicago for repurification and arrived in February 1944, and quantity organized, most of the expertise in plu- refabrication into different sizes and shipments of plutonium did not begin to tonium chemistry resided at Berkeley, shapes for the next-scheduled nuclear arrive at Los Alamos until May 1945. where plutonium was discovered in physics experiment. From the outset, it was clear that the December 1940, and at the Met Lab in Minimizing the time spent to solve purification of plutonium was the most Chicago. -
National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al. -
Novel Antimicrobial Agents Inhibiting Lipid II Incorporation Into Peptidoglycan Essay MBB
27 -7-2019 Novel antimicrobial agents inhibiting lipid II incorporation into peptidoglycan Essay MBB Mark Nijland S3265978 Supervisor: Prof. Dr. Dirk-Jan Scheffers Molecular Microbiology University of Groningen Content Abstract..............................................................................................................................................2 1.0 Peptidoglycan biosynthesis of bacteria ........................................................................................3 2.0 Novel antimicrobial agents ...........................................................................................................4 2.1 Teixobactin ...............................................................................................................................4 2.2 tridecaptin A1............................................................................................................................7 2.3 Malacidins ................................................................................................................................8 2.4 Humimycins ..............................................................................................................................9 2.5 LysM ........................................................................................................................................ 10 3.0 Concluding remarks .................................................................................................................... 11 4.0 references ................................................................................................................................. -
Fleming Vs. Florey: It All Comes Down to the Mold Kristin Hess La Salle University
The Histories Volume 2 | Issue 1 Article 3 Fleming vs. Florey: It All Comes Down to the Mold Kristin Hess La Salle University Follow this and additional works at: https://digitalcommons.lasalle.edu/the_histories Part of the History Commons Recommended Citation Hess, Kristin () "Fleming vs. Florey: It All Comes Down to the Mold," The Histories: Vol. 2 : Iss. 1 , Article 3. Available at: https://digitalcommons.lasalle.edu/the_histories/vol2/iss1/3 This Paper is brought to you for free and open access by the Scholarship at La Salle University Digital Commons. It has been accepted for inclusion in The iH stories by an authorized editor of La Salle University Digital Commons. For more information, please contact [email protected]. The Histories, Vol 2, No. 1 Page 3 Fleming vs. Florey: It All Comes Down to the Mold Kristen Hess Without penicillin, the world as it is known today would not exist. Simple infections, earaches, menial operations, and diseases, like syphilis and pneumonia, would possibly all end fatally, shortening the life expectancy of the population, affecting everything from family-size and marriage to retirement plans and insurance policies. So how did this “wonder drug” come into existence and who is behind the development of penicillin? The majority of the population has heard the “Eureka!” story of Alexander Fleming and his famous petri dish with the unusual mold growth, Penicillium notatum. Very few realize that there are not only different variations of the Fleming discovery but that there are also other people who were vitally important to the development of penicillin as an effective drug. -
Brilacidin First-In-Class Defensin-Mimetic Drug Candidate
Brilacidin First-in-Class Defensin-Mimetic Drug Candidate Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment April 20, 2020 Page # I. Brilacidin: Background Information 2 II. Brilacidin: Two Primary Mechanisms of Action 3 Membrane Disruption 4 Immunomodulatory 7 III. Brilacidin: Several Complementary Ways of Targeting COVID-19 10 Antiviral (anti-SARS-CoV-2 activity) 11 Immuno/Anti-Inflammatory 13 Antimicrobial 16 IV. Brilacidin: COVID-19 Clinical Development Pathways 18 Drug 18 Vaccine 20 Next Steps 24 V. Brilacidin: Phase 2 Clinical Trial Data in Other Indications 25 VI. AMPs/Defensins (Mimetics): Antiviral Properties 30 VII. AMPs/Defensins (Mimetics): Anti-Coronavirus Potential 33 VIII. The Broader Context: Characteristics of the COVID-19 Pandemic 36 Innovation Pharmaceuticals 301 Edgewater Place, Ste 100 Wakefield, MA 01880 978.921.4125 [email protected] Innovation Pharmaceuticals: Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment (April 20, 2020) Page 1 of 45 I. Brilacidin: Background Information Brilacidin (PMX-30063) is Innovation Pharmaceutical’s lead Host Defense Protein (HDP)/Defensin-Mimetic drug candidate targeting SARS-CoV-2, the virus responsible for COVID-19. Laboratory testing conducted at a U.S.-based Regional Biocontainment Laboratory (RBL) supports Brilacidin’s antiviral activity in directly inhibiting SARS-CoV-2 in cell-based assays. Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1, TNF- and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients. -
Lance Armstrong Has Something to Get Off His Chest
Texas Monthly July 2001: Lanr^ Armstrong Has Something to . Page 1 of 17 This copy is for your personal, non-commercial use only. For public distribution to your colleagues, clients or customers, contact [email protected] for reprint information and fees. (EJiiPfflNITHIS Lance Armstrong Has Something to Get Off His Chest He doesn't use performance-enhancing drugs, he insists, no matter what his critics in the European press and elsewhere say. And yet the accusations keep coming. How much scrutiny can the two-time Tour de France winner stand? by Michael Hall In May of last year, Lance Armstrong was riding in the Pyrenees, preparing for the upcoming Tour de France. He had just completed the seven-and-a-half-mile ride up Hautacam, a treacherous mountain that rises 4,978 feet above the French countryside. It was 36 degrees and raining, and his team's director, Johan Bruyneel, was waiting with a jacket and a ride back to the training camp. But Lance wasn't ready to go. "It was one of those moments in my life I'll never forget," he told me. "Just the two of us. I said, 'You know what, I don't think I got it. I don't understand it.1 Johan said, 'What do you mean? Of course you got it. Let's go.' I said, 'No, I'm gonna ride all the way down, and I'm gonna do it again.' He was speechless. And I did it again." Lance got it; he understood Hautacam—in a way that would soon become very clear. -
Cave Archaeology and the NSS: 1941–2006
George Crothers, P. Willey, and Patty Jo Watson – Cave archaeology and the NSS: 1941–2006. Journal of Cave and Karst Studies, v. 69, no. 1, p. 27–34. CAVE ARCHAEOLOGY AND THE NSS: 1941–2006 GEORGE CROTHERS1,P.WILLEY2, AND PATTY JO WATSON3 Abstract: Like most other branches of speleology, cave archaeology in the U.S. grew and developed significantly during the mid to late twentieth century. Originally viewed as marginal to mainstream Americanist archaeology, pursuit of prehistoric and historic archaeology underground is now widely accepted as making valuable contributions to knowledge of human past. The National Speleological Society played a central role in that development and continues to do so. We outline the establishment and growth of cave archaeology in North America, with special emphasis on relations between the NSS and archaeology performed in dark zone, deep cave interiors. INTRODUCTION 1920s and 1930s by ‘‘the Caveman,’’ as Neville was often called. The NSS has directly participated in cave archaeology Despite interest in cave archaeology within the NSS through cooperation, education, and conservation. Mem- governance and some portion of the membership during bers of the Society have made notable contributions to the the first few decades after the organization was formed, science by reporting the location of archaeological sites, systematic, long-term archaeological research by pro- participating in their investigation, and by equipping fessional archaeologists in the dark zones of big caves in scientists with the techniques and technology needed to the Americas did not get underway until the 1960s. There work safely in the cave environment (Damon, 1991, p. -
Opposing Effects of Dehydroepiandrosterone And
European Journal of Endocrinology (2000) 143 687±695 ISSN 0804-4643 EXPERIMENTAL STUDY Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells M O Canning, K Grotenhuis, H J de Wit and H A Drexhage Department of Immunology, Erasmus University Rotterdam, The Netherlands (Correspondence should be addressed to H A Drexhage, Lab Ee 838, Department of Immunology, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands; Email: [email protected]) Abstract Background: Dehydroepiandrosterone (DHEA) has been suggested as an immunostimulating steroid hormone, of which the effects on the development of dendritic cells (DC) are unknown. The effects of DHEA often oppose those of the other adrenal glucocorticoid, cortisol. Glucocorticoids (GC) are known to suppress the immune response at different levels and have recently been shown to modulate the development of DC, thereby influencing the initiation of the immune response. Variations in the duration of exposure to, and doses of, GC (particularly dexamethasone (DEX)) however, have resulted in conflicting effects on DC development. Aim: In this study, we describe the effects of a continuous high level of exposure to the adrenal steroid DHEA (1026 M) on the generation of immature DC from monocytes, as well as the effects of the opposing steroid DEX on this development. Results: The continuous presence of DHEA (1026 M) in GM-CSF/IL-4-induced monocyte-derived DC cultures resulted in immature DC with a morphology and functional capabilities similar to those of typical immature DC (T cell stimulation, IL-12/IL-10 production), but with a slightly altered phenotype of increased CD80 and decreased CD43 expression (markers of maturity). -
The Expert Panel on the Socio-Economic Impacts of Innovation Investments
INNOVATION IMPACTS: MEASUREMENT AND ASSESSMENT The Expert Panel on the Socio-economic Impacts of Innovation Investments Science Advice in the Public Interest INNOVATION IMPACTS: MEASUREMENT AND ASSESSMENT The Expert Panel on the Socio-economic Impacts of Innovation Investments ii Innovation Impacts: Measurement and Assessment THE COUNCIL OF CANADIAN ACADEMIES 180 Elgin Street, Suite 1401, Ottawa, ON Canada K2P 2K3 Notice: The project that is the subject of this report was undertaken with the approval of the Board of Governors of the Council of Canadian Academies. Board members are drawn from the Royal Society of Canada (RSC), the Canadian Academy of Engineering (CAE), and the Canadian Academy of Health Sciences (CAHS), as well as from the general public. The members of the expert panel responsible for the report were selected by the Council for their special competencies and with regard for appropriate balance. This report was prepared in response to a request from the Ontario Ministry of Research and Innovation. Any opinions, findings, or conclusions expressed in this publication are those of the authors, the Expert Panel on the Socio-economic Impacts of Innovation Investments, and do not necessarily represent the views of their organizations of affiliation or employment. Library and Archives Canada Cataloguing in Publication Innovation impacts: measurement and assessment [electronic resource] : socio-economic impacts of innovation investments of the government of Ontario/ Council of Canadian Academies. Includes bibliographical references and index. Electronic monograph in PDF format. Issued also in print format. ISBN 978-1-926558-58-5 1. Public investments – Ontario – Measurement. 2. Public investments – Ontario – Evaluation. 3. Technological innovations – Government policy – Ontario. -
Extending the Cure: Policy Responses to the Growing Threat Of
RAMANAN LAXMINARAYAN and ANUP MALANI with David Howard and David L. Smith EXTENDING THE CURE Policy responses to the growing threat of antibiotic resistance EXTENDING THE CURE RAMANAN LAXMINARAYAN and ANUP MALANI with David Howard and David L. Smith EXTENDING THE CURE Policy responses to the growing threat of antibiotic resistance © Resources for the Future 2007. All rights reserved. LIBRARY OF CONGRESS CATALOGING-IN-PUBLICATION DATA Laxminarayan, Ramanan. Extending the cure : policy responses to the growing threat of antibiotic resistance / by Ramanan Laxminarayan and Anup Malani ; with David Howard and David L. Smith. p. ; cm. Includes bibliographical references. ISBN 978-1-933115-57-3 (pbk. : alk. Paper) 1. Drug resistance in microorganisms—United States. 2. Drug resistance in microorganisms—Government policy—United States. I. Malani, Anup. II. Title. III. Title: Policy responses to the growing threat of antibiotic resistance. [DNLM: 1. Drug Resistance, Bacterial—United States. 2. Anti-Bacterial Agents—United States. 3. Drug Utilization—United States. 4. Health Policy—United States. QW 52 L425e 2007] QR177.L39 2007 616.9`041—dc22 2007008949 RESOURCES FOR THE FUTURE 1616 P Street, NW Washington, DC 20036-1400 USA www.rff.org ABOUT RESOURCES FOR THE FUTURE RFF is a nonprofit and nonpartisan organization that conducts independent research—rooted primarily in economics and other social sciences—on environmental, energy, natural resources, and public health issues. RFF is headquartered in Washington, D.C., but its research scope comprises programs in nations around the world. Founded in 1952, RFF pioneered the application of economics as a tool to develop more effective policy for the use and conservation of natural resources. -
Slate the CDC Comes out Swinging for Truvada, an HIV-Preventing
Slate The CDC Comes Out Swinging for Truvada, an HIV-Preventing Miracle Drug http://www.slate.com/blogs/outward/2014/05/15/cdc_supports_truvada_a_drug_that_preven ts_hiv.html?wpisrc=burger_bar By Mark Joseph Stern Truvada, which prevents HIV infection with a single daily pill, is the miracle drug that almost nobody takes. It prevents HIV more reliably than condoms, which can break. It has exceedingly minimal side effects. It’s covered by most private insurers and state Medicaid programs. But because of its novelty, doctors have been wary of prescribing it—and because of the absurd stigma it still carries, its target audience has been hesitant to take it. That’s all about to change. This week, as part of its cheerfully named Morbidity and Mortality Weekly Report, the CDC came out swinging for Truvada, unequivocally encouraging health care professionals to prescribe the drug to numerous at-risk groups. So far, those groups include anybody in a serodiscordant relationship, non-monogamous gay and bi men who sometimes have unprotected sex, straight men and women who sometimes have unprotected sex with drug users or bi men, and anybody who injects illicit drugs. To my mind, these categories are still a bit under-inclusive. It’s alarmingly easy to get HIV through anal sex: Condoms are more likely to break during anal intercourse than vaginal intercourse, and the HIV transmission risk from anal sex is 18 times higher than from vaginal penetration. As I’ve written before, there’s nothing inherently unhealthy about anal sex. But unless you’re in a monogamous relationship with someone who’s HIV-negative, the risk of HIV transmission during gay anal intercourse is always going to be a little higher than you’re probably comfortable with. -
2Nd INFANTRY REGIMENT
2nd INFANTRY REGIMENT 1110 pages (approximate) Boxes 1243-1244 The 2nd Infantry Regiment was a component part of the 5th Infantry Division. This Division was activated in 1939 but did not enter combat until it landed on Utah Beach, Normandy, three days after D-Day. For the remainder of the war in Europe the Division participated in numerous operations and engagements of the Normandy, Northern France, Rhineland, Ardennes-Alsace and Central Europe campaigns. The records of the 2nd Infantry Regiment consist mostly of after action reports and journals which provide detailed accounts of the operations of the Regiment from July 1944 to May 1945. The records also contain correspondence on the early history of the Regiment prior to World War II and to its training activities in the United States prior to entering combat. Of particular importance is a file on the work of the Regiment while serving on occupation duty in Iceland in 1942. CONTAINER LIST Box No. Folder Title 1243 2nd Infantry Regiment Unit Histories January 1943-June 1944 2nd Infantry Regiment Unit Histories, July-October 1944 2nd Infantry Regiment Histories, July 1944- December 1945 2nd Infantry Regiment After Action Reports, July-September 1944 2nd Infantry Regiment After Action Reports, October-December 1944 2nd Infantry Regiment After Action Reports, January-May 1945 2nd Infantry Regiment Casualty List, 1944-1945 2nd Infantry Regiment Unit Journal, 1945 2nd Infantry Regiment Narrative History, October 1944-May 1945 2nd Infantry Regiment History Correspondence, 1934-1936 2nd Infantry